A phase 2b multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of JNJ-81241459 for the treatment of participants with moderate to severe plaque psoriasis
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Antipsoriatics
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms Velocity
Most Recent Events
- 23 Jul 2024 Status changed from not yet recruiting to withdrawn prior to enrolment prior to site activation due to non-clinical findings.
- 13 Jun 2024 New trial record